MA-EVERBRIDGE-INC
29.3.2021 15:05:08 CEST | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG) today announced an expansion of its end-to-end market-leading and global Critical Event Management (CEM) SaaS platform, unveiling the most comprehensive integrated suite of digital and physical resiliency solutions for global organizations preparing for ‘the new normal’ in the post-pandemic world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005470/en/
Digitally transforming how organizations manage, respond to, and mitigate a crisis, as well as protecting revenue while improving cost efficiencies, Critical Event Management (CEM) represents a ‘must have’ set of standards and best practices that forward-looking CEOs and boards increasingly incorporate into how they govern operational risk from unplanned events. The expanded Everbridge CEM software solution suite provides organizations with the most comprehensive, end-to-end operating environment to take an ‘Assess , Locate , Act and Analyze’ closed loop approach to managing critical events in an increasingly volatile and uncertain global threat landscape, while delivering significant return on investment (ROI) through increased revenue and reduced costs.
“It is evident now, more than ever, that seamless communication, collaboration and complete oversight of all assets — infrastructure, digital, systems and workers — is invaluable to decision-making and for mitigating the financial and human cost of unforeseen events,” stated a March 2021 report entitled: Strategic Focus: Critical Event Management For EHS And Risk Management by Verdantix . “Critical event management (CEM) solutions help firms manage and respond effectively to such unforeseen events, ensuring resilience and saving lives.”
Today, over 5,600 global firms rely on Everbridge to keep their people safe and organizations running, faster. The Everbridge CEM Platform leverages over 450 out-of-the-box, pre-existing integrations and over 25,000 risk data sources, for organizations to gain clarity, act faster, and improve outcomes. Everbridge customers include some of the largest firms and leaders in their respective industries, including Fortune 1000 businesses such as Bristol Myers Squibb, Cisco, CVS Health, Goldman Sachs , Tiffany & Co. , Walgreens , and insurance providers like Anthem, chemical giant Dow , and telecom consumer electronics company Nokia, as well as some of Silicon Valley’s leading tech giants, global e-commerce firms, streaming media services, oil and natural gas providers, hotel and hospitality chains, automotive, courier delivery, aerospace and defense technology, air travel, and major car rental firms.
“Every organization possesses unique operational characteristics— a combination of technologies, physical locations, supply chains, brand, and most importantly, people— all of which are constantly changing,” said Ajay Nigam, Chief Product Officer for Everbridge. “With the rising challenges and opportunities associated with the Future of Work, Internet of Things (IoT), Big Data, and 5G, Everbridge provides the most comprehensive suite of software solutions for digitally transforming how organizations can help save lives and keep their physical and digital operations running through one unified platform, mapping risk intelligence with the automated tools to manage the full-lifecycle of a crisis or disruption.”
Everbridge’s Expanded CEM Solutions include:
CEM for People & Life Safety – representing the most flexible, robust, and scalable software solution for Duty of Care to keep people safe anywhere in the world. Everbridge provides a critical part of an organization’s Future of Work strategy as businesses shift to remote work and reimagine physical workspaces. Everbridge supports organizations with:
- Duty of Care for customers, remote and onsite employees, travelers, and field workers
- Employee engagement and retention
- Travel Risk management (TRM) & executive protection
- COVID-19 recovery and wellness checks
CEM for Operations & Business Continuity – keeping businesses and operations running, faster. The growing reliance on information technology requires organizations to rethink how they can withstand unexpected interruptions. Everbridge provides business continuity and security leaders with a common operating picture and automated tools to manage:
- Global security
- Business operations
- Incident management
- Crisis activation & task assignments
CEM for Supply Chain Risk – managing and optimizing supply chains and supply routes. As supply chains become more complex, manufacturing hubs, distribution routes and customer sites face increased risk from many different types of events and disruptions. A global pandemic, congested shipping routes, weather, political upheaval, and transportation delays can all expose organizations to the risk of unnecessary downtime, expediting fees, and failure to meet customer expectations, demand or service level requirements. Everbridge enables security and supply chain professionals to:
- Identify suppliers, route stops and optimized routes
- Automate threat identification
- Automate threat response
- Visualize supply chain risk
CEM for Smart Enterprise – accelerating digital transformation through smart automation, secure IoT management, big data and advanced analytics. With the capability of 5G supporting one million devices at a minimum for every square kilometer and with the number of IoT devices expected to approach 75 billion by 2025 , Everbridge enables organizations to utilize vast amounts of electronic data, including IoT sensors, to digitally transform how they manage the safety and security of their employees, customers, patients, first responders, residents, and visitors, as well as the resiliency of their operations and supply chain. Everbridge CEM for Smart Enterprise provides:
- Command center and visualization capabilities
- Integrated security
- IoT device control and wearable device integration
- Alarm management
CEM for Digital: Incidents & Cybersecurity – protecting an organization’s brand and reputation while providing resiliency for IT systems in an increasingly virtual world. The massive growth in digital service usage has empowered businesses while also opening them up to new vulnerabilities and a vastly expanded threat landscape. Everbridge CEM for Digital enables:
- Major incident management
- Application and infrastructure disruption
- Cybersecurity
- IT security operations
As per the Forrester report The Total Economic Impact™ of Everbridge CEM Platform: Cost Savings and Business Benefits Enabled by a CEM Platform (with COVID-19 addendum, dated March 2021), based on analysis assuming a multi-billion dollar, multinational corporation looking at cash flow analysis (risk-adjusted estimates), the payback period of deploying the CEM platform is approximately three months. The report went on to state, “All of the interviewed executives told Forrester that Everbridge helped them maintain business operations and revenue during critical events.”
The importance of critical event management solutions will be addressed at Everbridge’s Spring 2021 COVID-19: Road to Recovery (R2R) virtual leadership summit taking place May 26-27. Everbridge also announced today that 42nd President of the U.S. Bill Clinton will keynote the two-day global symposium addressing resilience strategies and best practices as global businesses, governments and economies seek recovery and a return to normalcy from the ongoing coronavirus pandemic. Click here to learn more and to register for the event .
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,600 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication modalities, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 26, 2021. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005470/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
